MARKET INDEX
KOSPI4,968.48▼ 2.59%
KOSDAQ650.06▼ 7.09%
S&P 5007,416.59▼ 1.92%
NASDAQ24,509.76▼ 2.49%
USD/KRW1,336.35▲ 0.53 (+0.04%)
WTI Crude$85.37▼ 0.41%
BTC/USD$64,295▼ 0.82%
KOSPI4,968.48▼ 2.59%
KOSDAQ650.06▼ 7.09%
S&P 5007,416.59▼ 1.92%
NASDAQ24,509.76▼ 2.49%
USD/KRW1,336.35▲ 0.53 (+0.04%)
WTI Crude$85.37▼ 0.41%
BTC/USD$64,295▼ 0.82%
헤더 좌
헤더 우
BREAKING
MARKET Times 공식 배너

Johnson & Johnson to Acquire Eye Drug Developer Odne, Backed by Blackstone Funding for Phase 3 Trials

Upfront payment of $2.2 billion with up to $1.125 billion in additional milestone-based payments. Blackstone to provide $750 million in development funding, securing milestone payments and royalties. Johnson & Johnson (J

Johnson & Johnson to Acquire Eye Drug Developer Odne, Backed by Blackstone Funding for Phase 3 Trials
MTIMES Archive / Photo

Upfront payment of $2.2 billion with up to $1.125 billion in additional milestone-based payments.

Blackstone to provide $750 million in development funding, securing milestone payments and royalties.

Johnson & Johnson (J&J) has announced a definitive agreement to acquire the ophthalmology drug developer Odne. Odne’s lead candidate for retinal diseases has demonstrated superior results in certain metrics during initial head-to-head clinical trials against existing therapies. The acquisition is valued at up to approximately $3.3 billion, including performance-based milestone payments, with Phase 3 clinical trials for the candidate to be funded by Blackstone.

J&J announced on the 16th (local time) that it signed a final agreement to acquire Odne for an upfront payment of $2.2 billion. An additional $1.125 billion may be paid contingent upon future regulatory and commercial milestones. The transaction is expected to close by the end of this year, subject to customary closing conditions and regulatory approvals.

Separately from the acquisition, funds managed by Blackstone Life Sciences will provide J&J with $750 million in development capital. This funding is contingent upon the completion of the Odne acquisition. According to J&J, the funds will be disbursed over several years and are intended to cover the full cost of Phase 3 development for Odne’s core candidate, OLN324.

In exchange, Blackstone will receive milestone payments based on regulatory and sales performance, as well as single-digit royalties. This arrangement allows J&J to mitigate the financial burden of Phase 3 trials by sharing future returns with the investor.

OLN324 is a bispecific antibody currently in development for wet age-related macular degeneration and diabetic macular edema. It simultaneously targets vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2), both of which are involved in retinal vascular diseases. The candidate was discovered by Innovent Biologics and has been co-developed with Odne.

J&J highlighted the drug's design, which enhances Ang2 inhibition and reduces the antibody's molecular size, as a key advantage. The company expects these characteristics to help more effectively manage retinal fluid and extend treatment intervals.

Odne compared OLN324 directly against faricimab in the randomized JADE study, which involved 164 patients. According to the company, patients with diabetic macular edema treated with OLN324 showed faster and more significant reductions in retinal edema. In wet macular degeneration, retinal thickness reduction was comparable to the faricimab group, but the 4mg OLN324 group showed faster and greater reduction in pigment epithelial detachment (PED) thickness. The company also stated that improvements in visual acuity were numerically greater in both conditions.

However, the JADE study was a Phase 1b trial, primarily designed to evaluate safety and tolerability. The improvements in visual acuity and retinal structure were analyzed as exploratory endpoints. The therapeutic potential observed in this early study must be validated for efficacy and safety in subsequent Phase 3 trials and pass regulatory review before commercialization can be achieved.

MARKET Times

MTIMES Global Editorial Statement

This analysis is provided for international business intelligence and informational purposes only. It does not constitute investment advice or a solicitation to buy or sell securities. For inquiries regarding licensing or syndication, please contact [email protected].

← More in CorporateBack to Top ↑

Related Market & Corporate Intelligence

Brokerages Temper KOSPI Expectations Amid Market VolatilityBrokerages Temper KOSPI Expectations Amid Market VolatilitySamsung and SK Hynix Face Antitrust Scrutiny in U.S. Over DRAM Supply StrategiesSamsung and SK Hynix Face Antitrust Scrutiny in U.S. Over DRAM Supply StrategiesGlobal Oil Market Divergence: Crude Surplus Meets Persistent Diesel TightnessGlobal Oil Market Divergence: Crude Surplus Meets Persistent Diesel TightnessFed's Warsh Warns of Employment Shocks Amid AI Growth ExpectationsFed's Warsh Warns of Employment Shocks Amid AI Growth Expectations
HomeTOP10AlmatenPicksCorpAlgiten